Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321

Barlogie, Bart; A. Kyle, Robert; C. Anderson, Kenneth; R. Greipp, Philip; M. Lazarus, Hillard; D. Hurd, David; McCoy, Jason; F. Moore, Dennis; R. Dakhil, Shaker; S. Lanier, Keith; Chapman, Robert; Cromer, Jeana; E. Salmon, Sydney; G.M. Durie, Brian; C. Crowley, John

doi:10.1200/jco.2005.04.5807

Public

Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321

Published in Journal of Clinical Oncology • Jan 24, 2006

Authors:

Bart Barlogie

Robert A. Kyle

Kenneth C. Anderson

Abstract

PURPOSE: Results of a prospective randomized trial conducted by the Intergroupe Francais du Myélome (IFM 90) indicated that autologous hematopoietic cell-supported high-dose therapy (HDT) effected higher complete response rates and extended progression-free survival (PFS) and overall survival (OS) c...

Subject

Medicine

Melphalan

Vincristine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!